Trial Search Results

ACTIV-6: COVID-19 Study of Repurposed Medications

The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Susanna Naggie, MD

Collaborator: National Center for Advancing Translational Science (NCATS)

Stanford Investigator(s):

Intervention(s):

  • Drug: Ivermectin
  • Drug: Fluvoxamine
  • Drug: Fluticasone
  • Other: Placebo

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Completed Informed Consent

   - Age ≥ 30 years old

   - Confirmed SARS-CoV-2 infection by any authorized or approved polymerase chain reaction
   (PCR) or antigen test collected within 10 days of screening

   - Two or more current symptoms of acute infection for ≤7 days. Symptoms include the
   following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches,
   chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell

Exclusion Criteria:

   - Prior diagnosis of COVID-19 infection (> 10 days from screening)

   - Current or recent (within 10 days of screening) hospitalization

   - Known allergy/sensitivity or any hypersensitivity to components of the study drug or
   placebo

   - Known contraindication(s) to study drug including prohibited concomitant medications

Ages Eligible for Study

30 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting